Takayasu Kurata
Hirakata, 5731191, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 119 publications
Establishment of an Onco-Ophthalmology Collaboration for Tisotumab Vedotin and Initial Experience with Ocular Adverse Events
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: August 04, 2026
Should supportive care be started before initiating cancer treatment?
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: May 21, 2026
Survival, toxicity, and sequencing: navigating the new first-line standard established by FLAURA2.
Journal: Translational lung cancer research
Published: February 14, 2026
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 11, 2026
AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer.
Journal: Molecular therapy. Oncology
Published: January 08, 2026
Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology.
Journal: Cancers
Published: December 10, 2025
PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.
Journal: Journal for immunotherapy of cancer
Published: November 17, 2025
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan.
Journal: Investigational new drugs
Published: August 30, 2025
Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan.
Journal: Respiratory investigation
Published: August 22, 2025
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study).
Journal: Cancer treatment and research communications
Published: July 29, 2025
Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response.
Journal: In vivo (Athens, Greece)
Published: July 29, 2025
Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2025
Last Updated: 09/26/2026